Widespread use of antibiotics has raised a concern about the Clostridium difficile infection (CDI). The prevalence has been alarmingly rising over the last decade with recurrence rates of 20-40%. Since long, metronidazole and vancomycin have been the antibiotics of choice for treatment of CDI. However, there is need for prophylactic therapies and new treatment options considering the risk of developing antibiotic resistance.
CDI has become the most frequent nosocomial infection that accounts for 15-39% cases of antibiotic associated diarrhea. Higher incidence and recurrence of CDI warrants use of prophylactic and new treatment options. There are a number of new strategic therapies under development and a few recently adopted for clinical use. Existing therapies: Metronidazole: Owing to its cost effectiveness and availability, metronidazole has been widely recommended for…
